Glaukos EBITDA 2014-2024 | GKOS

Glaukos EBITDA for the quarter ending June 30, 2024 was $-0.021B, a 6.58% increase year-over-year.

  • Glaukos 2023 EBITDA was -0.091B, a 105.67% increase from 2022.
  • Glaukos 2022 EBITDA was -0.044B, a 1220.58% decline from 2021.
  • Glaukos 2021 EBITDA was 0.004B, a 106.83% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Glaukos EBITDA 2014-2024 | GKOS

  • Glaukos 2023 EBITDA was -0.091B, a 105.67% increase from 2022.
  • Glaukos 2022 EBITDA was -0.044B, a 1220.58% decline from 2021.
  • Glaukos 2021 EBITDA was 0.004B, a 106.83% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$233.5B
Intuitive Surgical (ISRG)$174.1B
Alcon (ALC)$48.6B
IQVIA Holdings (IQV)$43.5B
Edwards Lifesciences (EW)$41.3B
IDEXX Laboratories (IDXX)$41.2B
DexCom (DXCM)$27.9B
STERIS (STE)$24.1B
SONOVA HOLDING (SONVY)$21.4B
Waters (WAT)$19.3B
Hologic (HOLX)$18.8B
Fresenius Medical Care AG KGaA (FMS)$12.4B
Sysmex ADR (SSMXY)$12.4B
Teleflex (TFX)$11.6B
Globus Medical (GMED)$9.4B
Penumbra (PEN)$7.3B
Masimo (MASI)$6B
TransMedics (TMDX)$5.1B
Integer Holdings (ITGR)$4.3B
PROCEPT BioRobotics (PRCT)$4.2B
Tandem Diabetes Care (TNDM)$2.9B
Inari Medical (NARI)$2.7B
LivaNova (LIVN)$2.6B
Veracyte (VCYT)$2.5B
Nihon Kohden (NHNKY)$2.5B
Elekta AB (EKTAY)$2.5B
RxSight (RXST)$2B
Integra LifeSciences Holdings (IART)$1.4B
Pulse Biosciences (PLSE)$1.1B
Silk Road Medical (SILK)$1.1B